(SRRK) Scholar Rock Holding - Ratings and Ratios
Monoclonal Antibodies, Inhibitor, Cancer, Spinal Muscular Atrophy
| Risk via 10d forecast | |
|---|---|
| Volatility | 80.4% |
| Value at Risk 5%th | 114% |
| Relative Tail Risk | -13.47% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.72 |
| Alpha | 29.33 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.592 |
| Beta | 1.308 |
| Beta Downside | 1.767 |
| Drawdowns 3y | |
|---|---|
| Max DD | 65.21% |
| Mean DD | 29.18% |
| Median DD | 28.78% |
Description: SRRK Scholar Rock Holding November 09, 2025
Scholar Rock Holding Corp. (NASDAQ: SRRK) is a U.S.-based biopharma that leverages its proprietary platform on the transforming growth factor-beta (TGF-β) superfamily to create monoclonal antibodies that selectively bind growth-factor precursors. The company’s scientific premise is that modulating these upstream signals can treat serious diseases where protein growth-factor signaling is a driver.
Its lead assets include Apitegromab, a myostatin-activation inhibitor currently in a Phase 3 trial for spinal muscular atrophy (SMA), and SRK-181, which has completed Phase 1 testing for cancers that are refractory to checkpoint-inhibitor therapies (e.g., anti-PD-1/PD-L1). The pipeline also targets neuromuscular, cardiometabolic, fibrotic, and iron-restricted anemia indications.
**External context (as of 2024):**
• The global SMA market is projected by industry analysts to exceed **$2.5 billion by 2028**, driven by expanding newborn screening and gene-therapy approvals (source: GlobalData, 2024).
• Biotech R&D spending in the United States is growing at a **~10 % CAGR** (2023-2028), reflecting strong capital inflows and a favorable regulatory environment for novel biologics (source: BIO, 2024).
• Scholar Rock reported **≈ $140 million of cash and cash equivalents** in its latest 10-Q filing (Q2 2024), giving it an estimated 12-18 month runway at current burn rates, though this assumes no major acquisition or partnership outlays.**
If you want a data-rich, unbiased view of SRRK’s valuation metrics and how they compare to sector peers, a quick look at ValueRay’s analyst dashboard can provide the next layer of insight.
SRRK Stock Overview
| Market Cap in USD | 3,596m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2018-05-24 |
| Return 12m vs S&P 500 | 22.0% |
| Analyst Rating | 4.60 of 5 |
SRRK Dividends
Currently no dividends paidSRRK Growth Ratios
| Metric | Value |
|---|---|
| CAGR 3y | 69.45% |
| CAGR/Max DD Calmar Ratio | 1.07 |
| CAGR/Mean DD Pain Ratio | 2.38 |
| Current Volume | 1938.1k |
| Average Volume | 1715.7k |
Piotroski VR‑10 (Strict, 0-10) 0.0
| error: Net Income check cannot be calculated (needs Net Income TTM and Revenue TTM) |
| FCFTA -0.67 (>2.0%) and ΔFCFTA 38.72pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.67 (>3.0%) and CFO -274.1m > Net Income -353.4m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 6.30 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (113.7m) change vs 12m ago 17.19% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover 0.0% (prev 6.51%; Δ -6.51pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -100.5 (EBITDA TTM -357.6m / Interest Expense TTM 2.54m) >= 6 (WARN >= 3) |
Altman Z'' -17.76
| (A) 0.80 = (Total Current Assets 390.7m - Total Current Liabilities 62.0m) / Total Assets 411.7m |
| (B) -2.94 = Retained Earnings (Balance) -1.21b / Total Assets 411.7m |
| warn (B) unusual magnitude: -2.94 — check mapping/units |
| (C) -0.86 = EBIT TTM -255.3m / Avg Total Assets 295.4m |
| (D) -7.25 = Book Value of Equity -1.21b / Total Liabilities 166.7m |
| Total Rating: -17.76 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 22.51
| 1. Piotroski 0.0pt |
| 2. FCF Yield -8.23% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.45 |
| 5. Debt/Ebitda 0.49 |
| 6. ROIC - WACC (= -67.41)% |
| 7. RoE -122.0% |
| 8. Rev. Trend -48.37% |
| 9. EPS Trend -89.32% |
What is the price of SRRK shares?
Over the past week, the price has changed by +26.44%, over one month by +36.17%, over three months by +10.52% and over the past year by +36.47%.
Is SRRK a buy, sell or hold?
- Strong Buy: 6
- Buy: 4
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the SRRK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 47.7 | 25.5% |
| Analysts Target Price | 47.7 | 25.5% |
| ValueRay Target Price | 36.7 | -3.5% |
SRRK Fundamental Data Overview November 18, 2025
P/S = 13.1358
P/B = 15.4146
Beta = 0.662
Revenue TTM = 0.0 USD
EBIT TTM = -255.3m USD
EBITDA TTM = -357.6m USD
Long Term Debt = 50.1m USD (from longTermDebt, last fiscal year)
Short Term Debt = 5.33m USD (from shortTermDebt, last quarter)
Debt = 110.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -176.7m USD (from netDebt column, last quarter)
Enterprise Value = 3.34b USD (3.60b + Debt 110.1m - CCE 369.6m)
Interest Coverage Ratio = -100.5 (Ebit TTM -255.3m / Interest Expense TTM 2.54m)
FCF Yield = -8.23% (FCF TTM -274.6m / Enterprise Value 3.34b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 812.0k) / Revenue TTM)
Tobins Q-Ratio = 8.10 (Enterprise Value 3.34b / Total Assets 411.7m)
Interest Expense / Debt = 1.21% (Interest Expense 1.33m / Debt 110.1m)
Taxrate = 21.0% (US default 21%)
NOPAT = -201.7m (EBIT -255.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.30 (Total Current Assets 390.7m / Total Current Liabilities 62.0m)
Debt / Equity = 0.45 (Debt 110.1m / totalStockholderEquity, last quarter 245.0m)
Debt / EBITDA = 0.49 (negative EBITDA) (Net Debt -176.7m / EBITDA -357.6m)
Debt / FCF = 0.64 (negative FCF - burning cash) (Net Debt -176.7m / FCF TTM -274.6m)
Total Stockholder Equity = 289.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -85.84% (Net Income -353.4m / Total Assets 411.7m)
RoE = -122.0% (Net Income TTM -353.4m / Total Stockholder Equity 289.8m)
RoCE = -75.09% (EBIT -255.3m / Capital Employed (Equity 289.8m + L.T.Debt 50.1m))
RoIC = -56.87% (negative operating profit) (NOPAT -201.7m / Invested Capital 354.6m)
WACC = 10.55% (E(3.60b)/V(3.71b) * Re(10.84%) + D(110.1m)/V(3.71b) * Rd(1.21%) * (1-Tc(0.21)))
Discount Rate = 10.84% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 22.35%
Fair Price DCF = unknown (Cash Flow -274.6m)
EPS Correlation: -89.32 | EPS CAGR: -40.42% | SUE: -0.47 | # QB: 0
Revenue Correlation: -48.37 | Revenue CAGR: -61.68% | SUE: 0.0 | # QB: 0
Additional Sources for SRRK Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle